Terms: = Prostate cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Treatment
1529 results:
1. [prostate cancer - from the patients' perspective].
Lewén K; Waller C; Grönberg H; Bratt O
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38651688
[TBL] [Abstract] [Full Text] [Related]
2. Role of oxygen reserve index monitoring in patients undergoing robot-assisted radical prostatectomy: a retrospective study.
Ryu JH; Jeon YT; Sim KM; Lee S; Oh AY; Koo CH
World J Urol; 2024 Apr; 42(1):232. PubMed ID: 38613597
[TBL] [Abstract] [Full Text] [Related]
3. Aberrant activated Notch1 promotes prostate enlargement driven by androgen signaling via disrupting mitochondrial function in mouse.
Kang JW; He JP; Liu YN; Zhang Y; Song SS; Xu QX; Wei SW; Lu L; Meng XQ; Xu L; Guo B; Su RW
Cell Mol Life Sci; 2024 Mar; 81(1):155. PubMed ID: 38538986
[TBL] [Abstract] [Full Text] [Related]
4. Contemporary Diagnostic Reporting for Prostatic Adenocarcinoma: Morphologic Aspects, Molecular Correlates, and Management Perspectives.
Muthusamy S; Smith SC
Adv Anat Pathol; 2024 May; 31(3):188-201. PubMed ID: 38525660
[TBL] [Abstract] [Full Text] [Related]
5. Targeting HOXA11-AS to mitigate prostate cancer via the glycolytic metabolism: In vitro and in vivo.
Zhang J; Li S; Zhang M; Wang Z; Xing Z
J Cell Mol Med; 2024 Apr; 28(8):e18227. PubMed ID: 38520207
[TBL] [Abstract] [Full Text] [Related]
6. Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-cancer Clinicogenomic Data set.
Kehl KL; Lavery JA; Brown S; Fuchs H; Riely G; Schrag D; Newcomb A; Nichols C; Micheel CM; Bedard PL; Sweeney SM; Fiandalo M; Panageas KS;
JCO Precis Oncol; 2024 Mar; 8():e2300489. PubMed ID: 38484212
[TBL] [Abstract] [Full Text] [Related]
7. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
8. Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
Guo L; Liu L; Liu Y; Yang T; Wang G; Liu J; Li S; Cai J
BMJ Open; 2024 Mar; 14(3):e080092. PubMed ID: 38458812
[TBL] [Abstract] [Full Text] [Related]
9. Five-year clinical outcomes of scanning carbon-ion radiotherapy for prostate cancer.
Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H
PLoS One; 2024; 19(3):e0290617. PubMed ID: 38457424
[TBL] [Abstract] [Full Text] [Related]
10. Conformity of ChatGPT recommendations with the AUA/SUFU guideline on postprostatectomy urinary incontinence.
Pinto VBP; de Azevedo MF; Wroclawski ML; Gentile G; Jesus VLM; de Bessa Junior J; Nahas WC; Sacomani CAR; Sandhu JS; Gomes CM
Neurourol Urodyn; 2024 Apr; 43(4):935-941. PubMed ID: 38451040
[TBL] [Abstract] [Full Text] [Related]
11. [Bladder cancer Detected Incidentally by Cystoscopy before Radical prostatectomy].
Oshiro H; Shimizu Y; Nakayasu R; Yamaguchi R; Utsunomiya N; Kanamaru S
Hinyokika Kiyo; 2024 Feb; 70(2):39-43. PubMed ID: 38447943
[TBL] [Abstract] [Full Text] [Related]
12. Multiobjective tree-based reinforcement learning for estimating tolerant dynamic treatment regimes.
Song Y; Wang L
Biometrics; 2024 Jan; 80(1):. PubMed ID: 38364801
[TBL] [Abstract] [Full Text] [Related]
13. Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning.
Kang Z; Zhao YX; Qiu RSQ; Chen DN; Zheng QS; Xue XY; Xu N; Wei Y
Cancer Immunol Immunother; 2024 Feb; 73(3):41. PubMed ID: 38349474
[TBL] [Abstract] [Full Text] [Related]
14. The practical clinical role of machine learning models with different algorithms in predicting prostate cancer local recurrence after radical prostatectomy.
Hu C; Qiao X; Hu C; Cao C; Wang X; Bao J
Cancer Imaging; 2024 Feb; 24(1):23. PubMed ID: 38326860
[TBL] [Abstract] [Full Text] [Related]
15. Keeping your best options open with AI-based treatment planning in prostate and cervix brachytherapy.
Dickhoff LRM; Scholman RJ; Barten DLJ; Kerkhof EM; Roorda JJ; Velema LA; Stalpers LJA; Pieters BR; Bosman PAN; Alderliesten T
Brachytherapy; 2024; 23(2):188-198. PubMed ID: 38296658
[TBL] [Abstract] [Full Text] [Related]
16. Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.
Chen JY; Chang CF; Huang SP; Huang CY; Yu CC; Lin VC; Geng JH; Li CY; Lu TL; Bao BY
BMC Med Genomics; 2024 Jan; 17(1):41. PubMed ID: 38287309
[TBL] [Abstract] [Full Text] [Related]
17. Effect of Concomitant Medications on treatment Response and Survival in De Novo Metastatic prostate cancer: Secondary Analysis of the LATITUDE Study.
Roy S; Saad F; Wallis CJD; Sun Y; Spratt DE; Akilla R; Kishan AU; Malone S; Morgan SC
Eur J Cancer; 2024 Mar; 199():113348. PubMed ID: 38262848
[TBL] [Abstract] [Full Text] [Related]
18. Transcriptional Inflammatory Signature in Healthy Donors and Different Radiotherapy cancer Patients.
O'Brien G; Kamuda M; Cruz-Garcia L; Polozova M; Tichy A; Markova M; Sirak I; Zahradnicek O; Widłak P; Ponge L; Polanska J; Badie C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256152
[TBL] [Abstract] [Full Text] [Related]
19. Identification of Molecular Markers Associated with prostate cancer Subtypes: An Integrative Bioinformatics Approach.
Granata I; Barboro P
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254687
[TBL] [Abstract] [Full Text] [Related]
20. Epidemiology of and Risk Factors in Postoperative Complications from Robotically Assisted Laparoscopic Radical prostatectomy in Contemporary National Surgical Quality Improvement Program Data.
Homer A; Golijanin B; Schmitt P; Bhatt V; Pareek G; Hyams ES
J Endourol; 2024 Mar; 38(3):270-275. PubMed ID: 38251639
[No Abstract] [Full Text] [Related]
[Next]
